The physicochemical properties and the in vivo AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and bis(7)-tacrine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 46, Issue 1, 2008, Pages 75-81

  Yu, Hua ^a,b   Li, Wen Ming ^b   Kan, Kelvin K W ^b   Ho, Jason M K ^b   Carlier, Paul R ^c   Pang, Yuan Ping ^d   Gu, Zhe Ming ^e   Zhong, Zuo ^f   Chan, Kelvin ^g   Wang, Yi Tao ^a   Han, Yi Fan ^b  

^a University of Macau   (Macao)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^d Mayo Clinic   (United States)

^e XENOBIOTIC LABORATORIES INC   (United States)

^f and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^g UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

AChE inhibition; Bis(12) hupyridone; Bis(7) tacrine; Dimer; Ionization constant; Lipophilicity; Solubility

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIMER; METHANOL; OCTANOL; PYRIDONE DERIVATIVE; TACRINE; TACRINE DERIVATIVE; WATER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME INHIBITION; IN VIVO STUDY; IONIC STRENGTH; IONIZATION; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STATISTICAL SIGNIFICANCE; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 36749038771     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2007.08.027     Document Type: Article

References (37)

1. Heppner F.L., Gandy S., and McLaurin J. Alzheimer Dis. Assoc. Disord. 18 (2004) 38-43
2. Viegas C.J., Bolzani Vda.S., Barreiro E.J., and Fraga C.A. Mini Rev. Med. Chem. 5 (2005) 915-926
3. Birks J. Cochrane Database Syst. Rev. 25 (2006) CD005593
4. Olsen C.E., Poulsen H.D., and Lublin H.K. Rev. Nord. J. Psychiatry 59 (2005) 71-77
5. Youdim M.B., and Buccafusco J.J. J. Neural Transm. 112 (2005) 519-537
6. Galisteo M., Rissel M., Sergent O., Chevanne M., Cillard J., Guillouzo A., and Lagadic-Gossmann D. J. Pharmacol. Exp. Ther. 294 (2000) 160-167
7. Han Y.F., Li C.P., Chow E., Wang H., Pang Y.P., and Carlier P.R. Bioorg. Med. Chem. 7 (1999) 2569-2575
8. Wong D.M., Greenblatt H.M., Dvir H., Carlier P.R., Han Y.F., Pang Y.P., Silman I., and Sussman J.L. J. Am. Chem. Soc. 125 (2003) 363-373
9. National Institute on Aging (NIA). 2004. Huperzine A in Alzheimer's disease. http://clinicaltrials.gov/show/NCT00083590.
10. Wang H., Carlier P.R., Ho W.L., Lee N.T., Pang Y.P., and Han Y.F. Zhongguo Yao Li Xue Bao 20 (1999) 211-217
11. Wang H., Carlier P.R., Ho W.L., Wu D.C., Lee N.T., Li C.P., Pang Y.P., and Han Y.F. Neuroreport 10 (1999) 789-793
12. Wu D.C., Xiao X.Q., Ng A.K., Chen P.M., Chung W., Lee N.T., Carlier P.R., Pang Y.P., Yu A.C., and Han Y.F. Neurosci. Lett. 288 (2000) 95-98
13. Xiao X.Q., Lee N.T., Carlier P.R., Pang Y.P., and Han Y.F. Neurosci. Lett. 290 (2000) 197-200
14. Camps P., and Munoz-Torrero D. Mini Rev. Med. Chem. 1 (2001) 163-174
15. Li W., Pi R., Chan H.H., Fu H., Lee N.T., Tsang H.W., Pu Y., Chang D.C., Li C., Luo J., Xiong K., Li Z., Xue H., Carlier P.R., Pang Y., Tsim K.W., Li M., and Han Y.F. J. Biol. Chem. 280 (2005) 18179-18188
16. Li C.Y., Wang H., Xue H., Carlier P.R., Hui K.M., Pang Y.P., Li Z.W., and Han Y.F. Neuroreport 10 (1999) 795-800
17. Li W., Lee N.T., Fu H., Kan K.K., Pang Y.P., Li M., Tsim K.W., Li X., and Han Y.F. Neuroreport 17 (2006) 471-474
18. Du D.M., and Carlier P.R. Curr. Pharm. Des. 10 (2004) 3141-3156
19. El-Gendy A.M., and Adejare A. Int. J. Pharm. 280 (2004) 47-55
20. Horter D., and Dressman J.B. Adv. Drug. Deliv. 46 (2001) 75-87
21. Pang Y.P., Quiram P., Jelacic T., Hong F., and Brimijoin S. J. Biol. Chem. 271 (1996) 23646-23649
22. Carlier P.R., Du D.M., Han Y.F., Liu J., Perola E., Williams I.D., and Pang Y.P. Angew. Chem. Int. Ed. Engl. 39 (2000) 1775-1777
23. Organization for Economic Cooperation and Development. Guidelines for The Testing of Chemicals, OECD 117, Partition Coefficient (n-octanol/water) (High Performance Liquid Chromatography (HPLC) Method), 1989, OECD, Paris, France.
24. Organization for Economic Cooperation and Development, Guidelines for The Testing of Chemicals, OECD 107, Partition Coefficient (n-octanol/water) (Shake Flask Method), 1995, OECD, Paris, France.
25. Seok Y.J., Yang K.S., and Kang S.O. Anal. Chim. Acta 306 (1995) 351-356
26. Ellman G.L., Courtney K.D., Andre Jr. V., and Feather-stone R.M. Biochem. Pharmacol. 7 (1961) 88-95
27. Bradford M.M. Anal. Biochem. 72 (1976) 248-254
28. Hansch C., Leo A., and Hoekman D. Exploring QSAR-Hydrophobic, Electronic, and Steric Constants ACS Professional Reference Book (1995), American Chemical Society, Washington, DC
29. Masumoto K., Takeyasu A., Oizumi K., and Kobayashi T. Yakugaku Zasshi 115 (1995) 213-220
30. Alain B., Mahmoud H., and Guy H. J. Liq. Chrom. Relat. Tech. 28 (2005) 1851-1866
31. Jaskari T., Vuorio M., Kontturi K., Urtti A., Manzanares J.A., and Hirvonen J. J. Control. Release 67 (2000) 179-190
32. Li W.M., Kan K.K.W., Pang Y.P., and Han Y.F. Curr Alzheimer Res. 4 (2007) 386-396
33. Gratton J.A., Abraham M.H., Bradbury M.W., and Chadha H.S. J. Pharm. Pharmacol. 49 (1997) 1211-1216
34. McEwen B.S. Mol. Psychiatry 2 (1997) 255-262
35. Wilkinson D.G., Francis P.T., Schwam E., and Payne-Parrish J. Drugs Aging 21 (2004) 453-478
36. Emilien G., Beyreuther K., Masters G.L., and Maloteaux J.M. Arch. Neurol. 57 (2000) 454-459
37. Harkany T., Hortobagyi T., Sasvari M., Konya C., Penke B., Luiten P.G., and Nyakas C. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 (1999) 963-1008